Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 8196560, 9 pages
http://dx.doi.org/10.1155/2016/8196560
Review Article

The Causes of HIV-Associated Cardiomyopathy: A Tale of Two Worlds

1School of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA
2Department of Medicine, Duke Clinical Research Institute and Duke Global Health Institute, Duke University Medical Center, Durham, NC 27705, USA

Received 6 November 2015; Accepted 15 December 2015

Academic Editor: Tomas Palecek

Copyright © 2016 Rebecca H. Lumsden and Gerald S. Bloomfield. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. UNAIDS, Fast-Track—Ending the AIDS Epidemic by 2030, UNAIDS, Geneva, Switzerland, 2014.
  2. G. S. Bloomfield, P. Khazanie, A. Morris et al., “HIV and noncommunicable cardiovascular and pulmonary diseases in low-and middle-income countries in the art era: what we know and best directions for future research,” Journal of Acquired Immune Deficiency Syndromes, vol. 67, no. 1, pp. S40–S53, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. I. S. Cohen, D. W. Anderson, R. Virmani et al., “Congestive cardiomyopathy in association with the acquired immunodeficiency syndrome,” The New England Journal of Medicine, vol. 315, no. 10, pp. 628–630, 1986. View at Publisher · View at Google Scholar
  4. G. S. Bloomfield, F. Alenezi, F. A. Barasa, R. Lumsden, B. M. Mayosi, and E. J. Velazquez, “Human immunodeficiency virus and heart failure in low- and middle-income countries,” JACC: Heart Failure, vol. 3, no. 8, pp. 579–590, 2015. View at Publisher · View at Google Scholar
  5. P. F. Currie, A. J. Jacob, A. R. Foreman, R. A. Elton, R. P. Brettle, and N. A. Boon, “Heart muscle disease related to HIV infection: prognostic implications,” British Medical Journal, vol. 309, no. 6969, pp. 1605–1607, 1994. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Remick, V. Georgiopoulou, C. Marti et al., “Heart failure in patients with human immunodeficiency virus infection: epidemiology, pathophysiology, treatment, and future research,” Circulation, vol. 129, no. 17, pp. 1781–1789, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Sliwa, M. J. Carrington, A. Becker, F. Thienemann, M. Ntsekhe, and S. Stewart, “Contribution of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic to de novo presentations of heart disease in the Heart of Soweto Study cohort,” European Heart Journal, vol. 33, no. 7, pp. 866–874, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. J. W. Magnani and G. W. Dec, “Myocarditis: current trends in diagnosis and treatment,” Circulation, vol. 113, no. 6, pp. 876–890, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Barbarini and G. Barbaro, “Incidence of the involvement of the cardiovascular system in HIV infection,” AIDS, vol. 17, supplement 1, pp. S46–S50, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Barbaro, “HIV-associated cardiomyopathy: etiopathogenesis and clinical aspects,” Herz, vol. 30, no. 6, pp. 486–492, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Barbaro, G. Di Lorenzo, B. Grisorio, and G. Barbarini, “Cardiac involvement in the acquired immunodeficiency syndrome: a multicenter clinical-pathological study,” AIDS Research and Human Retroviruses, vol. 14, no. 12, pp. 1071–1077, 1998. View at Publisher · View at Google Scholar
  12. A. Herskowitz, T. C. Wu, S. B. Willoughby et al., “Myocarditis and cardiotropic viral infection associated with severe left ventricular dysfunction in late-stage infection with human immunodeficiency virus,” ournal of the American College of Cardiology, vol. 24, no. 4, pp. 1025–1032, 1994. View at Google Scholar
  13. B. Longo-Mbenza, K. V. Seghers, M. Phuati, F. Nkiabungu Bikangi, and K. Mubagwa, “Heart involvement and HIV infection in African patients: determinants of survival,” International Journal of Cardiology, vol. 64, no. 1, pp. 63–73, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Barbaro and G. Barbarini, “Human immunodeficiency virus & cardiovascular risk,” Indian Journal of Medical Research, vol. 134, no. 6, pp. 898–903, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Pugliese, D. Isnardi, A. Saini, T. Scarabelli, R. Raddino, and D. Torre, “Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement,” Journal of Infection, vol. 40, no. 3, pp. 282–284, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Fiala, W. Popik, J.-H. Qiao et al., “HIV-1 induces cardiomyopathy by cardiomyocyte invasion and gp120, Tat, and cytokine apoptotic signaling,” Cardiovascular Toxicology, vol. 4, no. 2, pp. 97–107, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Twu, N. Q. Liu, W. Popik et al., “Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion- and death receptor-controlled pathways,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 22, pp. 14386–14391, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Barbaro, S. D. Fisher, and S. E. Lipshultz, “Pathogenesis of HIV-associated cardiovascular complications,” The Lancet Infectious Diseases, vol. 1, no. 2, pp. 115–124, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Lecoeur, A. Borgne-Sanchez, O. Chaloin et al., “HIV-1 Tat protein directly induces mitochondrial membrane permeabilization and inactivates cytochrome c oxidase,” Cell Death and Disease, vol. 3, article e282, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Barbaro, “Cardiovascular manifestations of HIV infection,” Circulation, vol. 106, no. 11, pp. 1420–1425, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Duan, H. Yao, G. Hu, X. Chen, A. K. Lund, and S. Buch, “HIV Tat induces expression of ICAM-1 in HUVECs: implications for miR-221/-222 in HIV-associated cardiomyopathy,” PLoS ONE, vol. 8, no. 3, Article ID e60170, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. P. F. Currie, J. H. Goldman, A. L. P. Caforio et al., “Cardiac autoimmunity in HIV related heart muscle disease,” Heart, vol. 79, no. 6, pp. 599–604, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. A. L. Kavanaugh-McHugh, A. Ruff, E. Perlman, N. Hutton, J. Modlin, and S. Rowe, “Selenium deficiency and cardiomyopathy in acquired immunodeficiency syndrome,” Journal of Parenteral and Enteral Nutrition, vol. 15, no. 3, pp. 347–349, 1991. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Ge and G. Yang, “The epidemiology of selenium deficiency in the etiological study of endemic diseases in China,” The American Journal of Clinical Nutrition, vol. 57, no. 2, supplement, pp. 259s–263s, 1993. View at Google Scholar · View at Scopus
  25. M. Twagirumukiza, E. Nkeramihigo, B. Seminega, E. Gasakure, F. Boccara, and G. Barbaro, “Prevalence of dilated cardiomyopathy in HIV-infected African patients not receiving HAART: a multicenter, observational, prospective, cohort study in Rwanda,” Current HIV Research, vol. 5, no. 1, pp. 129–137, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. M. P. Look, J. K. Rockstroh, G. S. Rao et al., “Serum selenium, plasma glutathione (GSH) and erythrocyte glutathione peroxidase (GSH-Px)-levels in asymptomatic versus symptomatic human immunodeficiency virus-1 (HIV-1)-infection,” European Journal of Clinical Nutrition, vol. 51, no. 4, pp. 266–272, 1997. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Bijl, J. P. Dieleman, M. Simoons, and M. E. Van Der Ende, “Low prevalence of cardiac abnormalities in an HIV-seropositive population on antiretroviral combination therapy,” Journal of Acquired Immune Deficiency Syndromes, vol. 27, no. 3, pp. 318–320, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. X. Burbano, M. J. Miguez-Burbano, K. McCollister et al., “Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV-infected participants,” HIV Clinical Trials, vol. 3, no. 6, pp. 483–491, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Chariot, H. Perchet, I. Monnet et al., “Dilated cardiomyopathy in HIV-infected patients,” The New England Journal of Medicine, vol. 340, no. 9, pp. 732–735, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. P. F. Currie and N. A. Boon, “Immunopathogenesis of HIV-related heart muscle disease: current perspectives,” AIDS, vol. 17, supplement 1, pp. S21–S28, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. B. S. Peters, J. Winer, D. N. Landon, A. Stotter, and A. J. Pinching, “Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS,” Quarterly Journal of Medicine, vol. 86, no. 1, pp. 5–15, 1993. View at Google Scholar · View at Scopus
  32. A. Herskowitz, S. B. Willoughby, K. L. Baughman, S. P. Schulman, and J. O. Bartlett, “Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: a report of six cases,” Annals of Internal Medicine, vol. 116, no. 4, pp. 311–313, 1992. View at Publisher · View at Google Scholar · View at Scopus
  33. S. E. Lipshultz, E. J. Orav, S. P. Sanders, A. R. Hale, K. Mcintosh, and S. D. Colan, “Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine,” The New England Journal of Medicine, vol. 327, no. 18, pp. 1260–1265, 1992. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Luo, Y. Ye, Z. Liu et al., “Assessment of cardiac diastolic dysfunction in HIV-infected people without cardiovascular symptoms in China,” International Journal of STD and AIDS, vol. 21, no. 12, pp. 814–818, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Ntsekhe and B. M. Mayosi, “Cardiac manifestations of HIV infection: an African perspective,” Nature Clinical Practice Cardiovascular Medicine, vol. 6, no. 2, pp. 120–127, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. B. M. Mayosi, “Contemporary trends in the epidemiology and management of cardiomyopathy and pericarditis in sub-Saharan Africa,” Heart, vol. 93, no. 10, pp. 1176–1183, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. G. S. Bloomfield, F. A. Barasa, J. A. Doll, and E. J. Velazquez, “Heart failure in Sub-Saharan Africa,” Current Cardiology Reviews, vol. 9, no. 2, pp. 157–173, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. B. M. Mayosi, C. S. Wiysonge, M. Ntsekhe et al., “Clinical characteristics and initial management of patients with tuberculous pericarditis in the HIV era: the Investigation of the Management of Pericarditis in Africa (IMPI Africa) registry,” BMC Infectious Diseases, vol. 6, article 2, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. B. M. Mayosi, M. Ntsekhe, J. Bosch et al., “Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis,” The New England Journal of Medicine, vol. 371, no. 12, pp. 1121–1130, 2014. View at Publisher · View at Google Scholar
  40. I. Schuster, G. J. Thöni, S. Edérhy et al., “Subclinical cardiac abnormalities in human immunodeficiency virus-infected men receiving antiretroviral therapy,” American Journal of Cardiology, vol. 101, no. 8, pp. 1213–1217, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. N. Reinsch, K. Neuhaus, S. Esser et al., “Prevalence of cardiac diastolic dysfunction in HIV-infected patients: results of the HIV-HEART study,” HIV Clinical Trials, vol. 11, no. 3, pp. 156–162, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. C. J. Holloway, N. Ntusi, J. Suttie et al., “Comprehensive cardiac magnetic resonance imaging and spectroscopy reveal a high burden of myocardial disease in HIV patients,” Circulation, vol. 128, no. 8, pp. 814–822, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Herskowitz, D. Vlahov, S. Willoughby et al., “Prevalence and incidence of left ventricular dysfunction in patients with human immunodeficiency virus infection,” The American Journal of Cardiology, vol. 71, no. 11, pp. 955–958, 1993. View at Publisher · View at Google Scholar · View at Scopus
  44. E. Cerrato, F. D'Ascenzo, G. Biondi-Zoccai et al., “Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era,” European Heart Journal, vol. 34, no. 19, pp. 1432–1436, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. F. Boccara, S. Lang, C. Meuleman et al., “HIV and coronary heart disease: time for a better understanding,” Journal of the American College of Cardiology, vol. 61, no. 5, pp. 511–523, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. D. Sun, Y. Wu, Y. Yuan, Y. Wang, W. Liu, and J. Yang, “Is the atherosclerotic process accentuated under conditions of HIV infection, antiretroviral therapy, and protease inhibitor exposure? Meta-analysis of the markers of arterial structure and function,” Atherosclerosis, vol. 242, no. 1, pp. 109–116, 2015. View at Publisher · View at Google Scholar
  47. E. R. Feeney and P. W. G. Mallon, “HIV and HAART-associated dyslipidemia,” Open Cardiovascular Medicine Journal, vol. 5, pp. 49–63, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. N. Friis-Møller, R. Weber, P. Reiss et al., “Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study,” AIDS, vol. 17, no. 8, pp. 1179–1193, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. S. D. Fisher, T. L. Miller, and S. E. Lipshultz, “Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis,” Atherosclerosis, vol. 185, no. 1, pp. 1–11, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. S. D. Holmberg, A. C. Moorman, J. M. Williamson et al., “Protease inhibitors and cardiovascular outcomes in patients with HIV-1,” The Lancet, vol. 360, no. 9347, pp. 1747–1748, 2002. View at Publisher · View at Google Scholar · View at Scopus
  51. S. W. Worm, C. Sabin, R. Weber et al., “Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study,” Journal of Infectious Diseases, vol. 201, no. 3, pp. 318–330, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. C. Bavinger, E. Bendavid, K. Niehaus et al., “Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review,” PLoS ONE, vol. 8, no. 3, Article ID e59551, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Damasceno, B. M. Mayosi, M. Sani et al., “The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries: results of the sub-Saharan Africa survey of heart failure,” Archives of Internal Medicine, vol. 172, no. 18, pp. 1386–1394, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. C. Bouramoue and J. Ekoba, “The heart and AIDS,” Médecine Tropicale (Mars), vol. 56, no. 3, supplement, pp. 33–39, 1996. View at Google Scholar
  55. K. Sliwa, B. A. Davison, B. M. Mayosi et al., “Readmission and death after an acute heart failure event: predictors and outcomes in sub-Saharan Africa: results from the THESUS-HF registry,” European Heart Journal, vol. 34, no. 40, pp. 3151–3159, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. P. Singh, A. Hemal, S. Agarwal, and D. Kumar, “Cardiac manifestations in HIV infected children,” The Indian Journal of Pediatrics, vol. 82, no. 3, pp. 230–234, 2015. View at Publisher · View at Google Scholar · View at Scopus
  57. T. J. Starc, S. E. Lipshultz, K. A. Easley et al., “Incidence of cardiac abnormalities in children with human immunodeficiency virus infection: the prospective P2C2 HIV study,” Journal of Pediatrics, vol. 141, no. 3, pp. 327–335, 2002. View at Publisher · View at Google Scholar · View at Scopus
  58. E. Braunwald, “Heart failure,” JACC: Heart Failure, vol. 1, no. 1, pp. 1–20, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. C. W. Yancy, M. Jessup, B. Bozkurt et al., “2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines,” Circulation, vol. 128, no. 16, pp. e240–e327, 2013. View at Publisher · View at Google Scholar
  60. W. G. Harmon, G. H. Dadlani, S. D. Fisher, and S. E. Lipshultz, “Myocardial and pericardial disease in HIV,” Current Treatment Options in Cardiovascular Medicine, vol. 4, no. 6, pp. 497–509, 2002. View at Publisher · View at Google Scholar
  61. A. Frustaci, N. Petrosillo, M. Francone, R. Verardo, G. Ippolito, and C. Chimenti, “Biopsy-proven autoimmune myocarditis in HIV-associated dilated cardiomyopathy,” BMC Infectious Diseases, vol. 14, article 729, 2014. View at Publisher · View at Google Scholar
  62. S. E. Lipshultz, E. J. Orav, S. P. Sanders, and S. D. Colan, “Immunoglobulins and left ventricular structure and function in pediatric HIV infection,” Circulation, vol. 92, no. 8, pp. 2220–2225, 1995. View at Publisher · View at Google Scholar · View at Scopus
  63. F. Agüero, M. A. Castel, S. Cocchi et al., “An update on heart transplantation in human immunodeficiency virus-infected patients,” American Journal of Transplantation, 2015. View at Publisher · View at Google Scholar
  64. L. H. Calabrese, M. Albrecht, J. Young et al., “Successful cardiac transplantation in an HIV-1—infected patient with advanced disease,” The New England Journal of Medicine, vol. 348, no. 23, pp. 2323–2328, 2003. View at Publisher · View at Google Scholar · View at Scopus
  65. N. Uriel, U. P. Jorde, V. Cotarlan et al., “Heart transplantation in human immunodeficiency virus-positive patients,” Journal of Heart and Lung Transplantation, vol. 28, no. 7, pp. 667–669, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. N. Uriel, N. Nahumi, P. C. Colombo et al., “Advanced heart failure in patients infected with human immunodeficiency virus: is there equal access to care?” Journal of Heart and Lung Transplantation, vol. 33, no. 9, pp. 924–930, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. D. B. Sims, N. Uriel, J. González-Costello et al., “Human immunodeficiency virus infection and left ventricular assist devices: a case series,” The Journal of Heart and Lung Transplantation, vol. 30, no. 9, pp. 1060–1064, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Ledwidge, J. Gallagher, C. Conlon et al., “Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial,” The Journal of the American Medical Association, vol. 310, no. 1, pp. 66–74, 2013. View at Publisher · View at Google Scholar · View at Scopus
  69. R. Carrillo-Jimenez, T. L. Treadwell, H. Goldfine, A. Buenano, G. A. Lamas, and C. H. Hennekens, “Brain natriuretic peptide and HIV-related cardiomyopathy,” The AIDS Reader, vol. 12, no. 11, pp. 501–503, 508, 2002. View at Google Scholar
  70. U. S. Kristoffersen, A. M. Lebech, J. Gerstoft et al., “Right and left cardiac function in HIV-infected patients investigated using radionuclide ventriculography and brain natriuretic peptide: a 5-year follow-up study,” HIV Medicine, vol. 9, no. 3, pp. 180–186, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. A. Mansoor, K. Althoff, S. Gange et al., “Elevated NT-pro-BNP levels are associated with comorbidities among HIV-infected women,” AIDS Research and Human Retroviruses, vol. 25, no. 10, pp. 997–1004, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. E. A. Secemsky, R. Scherzer, E. Nitta et al., “Novel biomarkers of cardiac stress, cardiovascular dysfunction, and outcomes in HIV-infected individuals,” JACC: Heart Failure, vol. 3, no. 8, pp. 591–599, 2015. View at Publisher · View at Google Scholar
  73. Access to Antiretroviral Drugs in Low- and Middle-Income Countries, World Health Organization, Geneva, Switzerland, 2014.